Explore more publications!
Louisiana Tech Review
Got News to Share?

Louisiana Tech Review: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Louisiana Tech Review.

February 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28

March 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

Press releases published on January 16, 2026

Krown Coin Reaches $212.2 Million Market Capitalization Within 72 Hours of Launch
Jan. 16, 2026

Krown Coin Reaches $212.2 Million Market Capitalization Within 72 Hours of Launch

Indeterminate EIN Presswire
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
Jan. 16, 2026

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

Indeterminate GlobeNewswire
DBV Technologies annonce avoir reçu un produit brut de 166,7 millions d'euros suite à l'exercice intégral des Bons de Souscription (BS) issus des ABSAs et des BS issus des PFW-BS-PFW émis dans le cadre de son financement de mars 2025
Jan. 16, 2026

DBV Technologies annonce avoir reçu un produit brut de 166,7 millions d'euros suite à l'exercice intégral des Bons de Souscription (BS) issus des ABSAs et des BS issus des PFW-BS-PFW émis dans le cadre de son financement de mars 2025

Indeterminate GlobeNewswire
VERSES® Restructures to Focus on Core Target Market
Jan. 16, 2026

VERSES® Restructures to Focus on Core Target Market

Indeterminate GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jan. 16, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Jan. 16, 2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Aduro Clean Technologies gibt Ergebnisse für das zweite Quartal des Geschäftsjahres 2026 bekannt und informiert über den aktuellen Stand des Geschäfts
Jan. 16, 2026

Aduro Clean Technologies gibt Ergebnisse für das zweite Quartal des Geschäftsjahres 2026 bekannt und informiert über den aktuellen Stand des Geschäfts

Indeterminate GlobeNewswire
Aduro Clean Technologies présente les résultats financiers de son deuxième trimestre 2026 et fait le point sur ses activités
Jan. 16, 2026

Aduro Clean Technologies présente les résultats financiers de son deuxième trimestre 2026 et fait le point sur ses activités

Indeterminate GlobeNewswire
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan. 16, 2026

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
Jan. 16, 2026

Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency

Indeterminate GlobeNewswire
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jan. 16, 2026

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jan. 16, 2026

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan. 16, 2026

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Jan. 16, 2026

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Indeterminate GlobeNewswire
CORRECTION - American Rebel Holdings, Inc. (NASDAQ: AREB) and American Rebel Light Beer Charge Into 2026: Virginia’s Lawrence Distributing Company Added as Distribution Growth Accelerates and Retail Rollouts Expand
Jan. 16, 2026

CORRECTION - American Rebel Holdings, Inc. (NASDAQ: AREB) and American Rebel Light Beer Charge Into 2026: Virginia’s Lawrence Distributing Company Added as Distribution Growth Accelerates and Retail Rollouts Expand

Indeterminate GlobeNewswire
How A/V Systems Support Home Education and Study Environments
Jan. 16, 2026

How A/V Systems Support Home Education and Study Environments

Indeterminate EIN Presswire
Metabo Drops Investigated (REPORT 2026) in the Frame of General Debates in Metabolic Health, Supplement Form, and Informed Consumer Analysis
Jan. 16, 2026

Metabo Drops Investigated (REPORT 2026) in the Frame of General Debates in Metabolic Health, Supplement Form, and Informed Consumer Analysis

Indeterminate GlobeNewswire
Michael Harrington Highlights QuantCore 5.0 Deployment as VMA Community Updates AI Analysis Infrastructure
Jan. 16, 2026

Michael Harrington Highlights QuantCore 5.0 Deployment as VMA Community Updates AI Analysis Infrastructure

Indeterminate GlobeNewswire
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
Jan. 16, 2026

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

Indeterminate GlobeNewswire
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
Jan. 16, 2026

First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions